TARC and IL-5 expression correlates with tissue eosinophilia in peripheral T-cell lymphomas

Leukemia Research

Volumn 32, Issue 9, 2008, Pages 1431-1438

  Thielen, Caroline ^a   Radermacher, Vincent ^a   Trimeche, Mounir ^b   Roufosse, Florence ^c,d   Goldman, Michel ^d   Boniver, Jacques ^a   de Leval, Laurence ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b FARHAT HACHED HOSPITAL   (Tunisia)

^c ERASME HOSPITAL   (Belgium)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Chemokine; Eosinophilia; Eotaxin; IL 5; Immunohistochemistry; RANTES; T cell lymphoma; TARC

Indexed keywords

EOTAXIN; INTERLEUKIN 5; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EOSINOPHIL; EOSINOPHILIA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHEMOKINE CCL11; CHEMOKINE CCL17; CHEMOKINE CCL5; EOSINOPHILIA; EOSINOPHILS; FEMALE; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-5; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; PROGNOSIS;

EID: 43049156415     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.02.016     Document Type: Article

References (53)

1. Jacobsen E.A., Taranova A.G., Lee N.A., and Lee J.J. Eosinophils: singularly destructive effector cells or purveyors of immunoregulation?. J Allergy Clin Immunol 119 (2007) 1313-1320
2. Roufosse F., Goldman M., and Cogan E. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. Semin Respir Crit Care Med 27 (2006) 158-170
3. Simon H.U., Plötz S.G., Dummer R., and Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. New Engl J Med 341 (1999) 1112-1120
4. Roufosse F., Schandené L., Sibille C., Willard-Gallo K., Kennes B., Efira A., et al. Clonal Th2 lymphocytes in patients with idiopathic hypereosinophilic syndrome. Br J Haematol 109 (2000) 540-548
5. Vaklavas C., Tefferi A., Butterfield J., Ketterling R., Verstovsek S., Kantarjian H., et al. 'Idiopathic' eosinophilia with an occult T-cell clone: prevalence and clinical course. Leuk Res 31 (2007) 691-694
6. de Lavareille A., Roufosse F., Schandené L., Stordeur P., Cogan E., and Goldman M. Clonal Th2 cells associated with chronic hypereosinophilia: TARC-induced CCR4 down-regulation in vivo. Eur J Immunol 31 (2001) 1037-1046
7. Imai T., Nagira M., Takagi S., Kazizaki M., Nishimura M., Wang J., et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 11 (1999) 81-88
8. Enblad G., Sundstrom C., and Glimelius B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol 11 (1993) 187-193
9. von Wasielewski R., Seth S., Franklin J., Fisher R., Hübner K., Hansmann M.L., et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 95 (2000) 1207-1213
10. Keresztes K., Szollosi Z., Simon Z., Tarkanyi I., Nemes Z., and Illes A. Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin's lymphoma. Pathol Oncol Res 13 (2007) 237-242
11. Murata K., Yamada Y., Kamihira S., Atogami S., Tsukasaki K., Momita S., et al. Frequency of eosinophilia in adult T-cell leukemia/lymphoma. Cancer 69 (1992) 966-971
12. Samoszuk M., Ramzi E., and Cooper D.L. Interleukin-5 mRNA in three T-cell lymphomas with eosinophilia. Am J Hematol 42 (1993) 402-404
13. Gallamini A., Carbone A., Lista P., Cavallero G., Reato G., Fruttero A., et al. Intestinal T-cell lymphoma with massive tissue and blood eosinophilia mediated by IL-5. Leuk Lymphoma 17 (1995) 155-161
14. Ionescu M.A., Rivet J., Daneshpoury M., Briere J., Morel P., and Janin A. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol 52 (2005) 32-39
15. Yamaguchi Y., Suda T., Ohta S., Tominaga K., Miura Y., and Kasahara T. Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood 78 (1991) 2542-2547
16. Sanderson C.J. Interleukin-5, eosinophils and disease. Blood 79 (1992) 3101-3109
17. Rothenberg M.E., and Hogan S.P. The eosinophil. Annu Rev Immunol 24 (2006) 147-174
18. Schall T.J., Bacon K., Toy K.J., and Goddel D.V. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347 (1990) 669-671
19. Dahinden C.A., Geiser T., Brunner T., von Tscarner V., Caput D., Ferrara P., et al. Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine. J Exp Med 179 (1994) 751-756
20. Ortiz B.D., Nelson P.J., and Krensky A.M. The RANTES gene and the regulation of its expression. In: Krensky A.M. (Ed). Biology of the chemokine RANTES. (1995), Springer-Verlag, Austin (TX) 87-99
21. Sallusto F., Mackay C., and Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277 (1997) 2005-2007
22. White J.R., Imburgia C., Dul E., Appelbaum E., O'Donnell K., O'Shannessy D.J., et al. Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils. J Leukoc Biol 62 (1997) 667-675
23. Maggio E., van den Berg A., Diepstra A., Kluiver J., Visser L., and Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 13 (2002) 52-56
24. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project. Blood 89 (1997) 3909-3918
25. Jaffe E., Harris N., Stein H., and Vardiman J. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues. In: Kleihues P., and Sobin L. (Eds). World Health Organization classification of tumours (2001), IARC Press, Lyon
26. Hashimoto S., Suzuki T., Dong H.Y., Nagai S., Yamazaki N., and Matsushima K. Serial analysis of gene expression in human monocyte-derived dendritic cells. Blood 94 (1999) 845-852
27. Sekiya T., Miyamasu M., Imanishi M., Yamada H., Nakajima T., Yamaguchi M., et al. Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells. J Immunol 165 (2000) 2205-2213
28. Liu L.Y., Bates M.E., Jarjour N.N., Busse W.W., Bertics P.J., and Kelly E.A. Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-alpha. J Immunol 179 (2007) 4840-4848
29. van den Berg A., Visser L., and Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrating Hodgkin's lymphoma. Am J Pathol 154 (1999) 1685-1691
30. Shimauchi T., Imai S., Hino R., and Tokura Y. Production of thymus and activation-regulated chemokine and macrophage-derived chemokine by CCR4+ adult T-cell leukemia cells. Clin Cancer Res 11 (2005) 2427-2435
31. Peh S., Kim L., and Poppema S. TARC, a CC chemokine, is frequently expressed in classical Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma. Am J Surg Pathol 25 (2001) 925-929
32. Yu B., Koga T., Urabe K., Moroi Y., Maeda S., Yanagihara Y., et al. Differential regulation of thymus- and activation-regulated chemokine induced by IL-4, IL-13, TNF-alpha and IFN-gamma in human keratinocyte and fibroblast. J Dermatol Sci 30 (2002) 29-36
33. Xia T., Fujita H., Saeki H., Mitsui H., Sugaya M., Tada Y., et al. Thymus and activation-regulated chemokine (TARC/CCL17) produced by mouse epidermal langerhans cells is up-regulated by TNF-alpha and IL-4 and down-regulated by IFN-gamma. Cytokine 23 (2003) 126-132
34. Liddiard K., Welch J.S., Lozach J., Heinz S., Glass C.K., and Greaves D.R. Interleukin-4 induction of the CC chemokine TARC (CCL17) in murine macrophages is mediated by multiple STAT6 sites in the TARC gene promoter. BMC Mol Biol 7 (2006) 45
35. Wirnsberger G., Hebenstreit D., Posselt G., Horejs-Hoeck J., and Duschl A. IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites. Eur J Immunol 36 (2006) 1882-1891
36. Suzuki Y., Rahman M., and Mitsuya H. Diverse transcriptional response of CD4+ T cells to stromal cell-derived factor (SDF)-1: cell survival promotion and priming effects of SDF-1 on CD4+ T cells. J Immunol 167 (2001) 3064-3073
37. Thelen M. Dancing to the tune of chemokines. Nat Immunol 2 (2001) 129-134
38. Weihrauch M.R., Manzke O., Beyer M., Haverkamp H., Diehl V., Bohlen H., et al. Elevated serum levels of CC thymus and activation-regulated chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res 65 (2005) 5516-5519
39. Paul C.C., Keller J.R., Armpriester J.M., and Baumann M.A. Epstein-Barr virus transformed b lymphocytes produce interleukin-5. Blood 75 (1990) 1400-1403
40. Suchin K.R., Cassin M., Gottleib S.L., Sood S., Cucchiara A.J., Vonderheid E.C., et al. Increased interleukin 5 production in eosinophilic Sezary syndrome; regulation by interferon alfa and interleukin 12. J Am Acad Dermatol 44 (2001) 28-32
41. Fermand J.P., Mitjavila M.T., Le Couedic J.P., Tsapis A., Berger R., Modigliani R., et al. Role of granulocyte-macrophage colony-stimulating factor, interleukin-3 and interleukin-5 in the eosinophilia associated with T cell lymphoma. Br J Haematol 83 (1993) 359-364
42. Samoszuk M., and Nansen L. Detection of interleukin-5 mRNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 75 (1990) 13-16
43. Brugnoni D., Airo P., Rossi G., Bettinardi A., Simon H.W., Garza L., et al. A case of HES is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood 87 (1996) 1416-1422
44. Went P., Agostinelli C., Gallamini A., Piccaluga P., Ascani S., Sabattini E., et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 24 (2006) 2472-2479
45. Dorfman D., van den Elzen P., Weng A., Shahsafaei A., and Glimcher L. Differential expression of T-bet, a T-box transcription factor required for Th1 T-cell development, in peripheral T-cell lymphomas. Am J Clin Pathol 120 (2003) 866-873
46. Tsuchiya T., Ohshima K., Karube K., Yamaguchi T., Suefuji H., Hamasaki M., et al. Th1, Th2 and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood 103 (2004) 236-241
47. Shi H. Eosinophils function as antigen-presenting cells. J Leukoc Biol 76 (2004) 520-527
48. Kita H. The eosinophil: a cytokine-producing cell?. J Allergy Clin Immunol 97 (1996) 889-892
49. Lacy P., and Moqbel R. Eosinophil cytokines. Chem Immunol 76 (2000) 134-155
50. MacKenzie J.R., Mattes J., Dent L.A., and Foster P.S. Eosinophils promote allergic disease of the lung by regulating CD4+ Th2 lymphocyte function. J Immunol 167 (2001) 3146-3155
51. Van Damme J., Struyf S., Wuyts A., Van Coillie E., Menten P., Schols D., et al. The role of CD26.DPP IV in chemokine processing. Chem Immunol 72 (1999) 42-56
52. Oravecz T., Pall M., Roderiquez G., Gorrell M.D., Ditto M., Nguyen N.Y., et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 186 (1997) 1865-1872
53. Struyf S., Proost P., Schols D., De Clercq E., Opdenakker G., Lenaerts J.P., et al. CD26 dipeptidyl-peptidase IV down-regulated the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 162 (1999) 4903-4909